Suppr超能文献

慢性肾脏病患者肺动脉高压的诊断与治疗。

Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.

机构信息

Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX.

Micheal E DeBakey Veterans Affairs Medical Center, Department of Medicine, Baylor College of Medicine, Houston, TX; Sections of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX.

出版信息

Am J Kidney Dis. 2020 Jun;75(6):935-945. doi: 10.1053/j.ajkd.2019.12.005. Epub 2020 Mar 19.

Abstract

Pulmonary hypertension (PH) is a highly prevalent and important condition in adults with chronic kidney disease (CKD). In this review, we summarize the definition of PH, discuss its pathophysiology and classifications, and describe diagnostic and management strategies in patients with CKD, including those with kidney failure treated by kidney replacement therapy. In the general population, PH is classified into 5 groups based on clinical presentation, pathology, hemodynamics, and management strategies. In this classification system, PH in CKD is placed in a diverse group with unclear or multifactorial mechanisms, although underlying cardiovascular disease may account for most cases. CKD may itself directly incite pulmonary circulatory dysfunction and remodeling through uremic toxins, inflammation, endothelial dysfunction, and altered vasoregulation. Despite several studies describing the higher prevalence of PH in CKD and kidney failure, along with an association with poor outcomes, high-quality evidence is not available for its diagnostic and management strategies in those with CKD. In CKD not requiring kidney replacement therapy, volume management along with treatment of underlying risk factors for PH are critical. In those receiving hemodialysis, options are limited and transition to peritoneal dialysis may be considered if recurrent hypotension precludes optimal volume control.

摘要

肺动脉高压(PH)是慢性肾脏病(CKD)成人中一种高发且重要的病症。在这篇综述中,我们总结了 PH 的定义,讨论了其病理生理学和分类,并描述了 CKD 患者的诊断和管理策略,包括接受肾脏替代治疗的肾衰竭患者。在一般人群中,PH 根据临床表现、病理学、血液动力学和管理策略分为 5 组。在这个分类系统中,CKD 中的 PH 被归入一个机制不明确或多因素的多样化组别,尽管潜在的心血管疾病可能占大多数病例。CKD 本身可能通过尿毒症毒素、炎症、内皮功能障碍和血管调节改变直接引起肺循环功能障碍和重塑。尽管有几项研究描述了 CKD 和肾衰竭患者中 PH 的患病率更高,并与不良结局相关,但对于 CKD 患者的 PH 诊断和管理策略,尚无高质量的证据。在不需要肾脏替代治疗的 CKD 中,容量管理以及治疗 PH 的潜在危险因素至关重要。对于接受血液透析的患者,选择有限,如果反复低血压妨碍了最佳容量控制,则可以考虑过渡到腹膜透析。

相似文献

1
Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.慢性肾脏病患者肺动脉高压的诊断与治疗。
Am J Kidney Dis. 2020 Jun;75(6):935-945. doi: 10.1053/j.ajkd.2019.12.005. Epub 2020 Mar 19.
4
Pulmonary Hypertension Subtypes and Mortality in CKD.慢性肾脏病相关肺动脉高压的亚型与死亡率
Am J Kidney Dis. 2020 May;75(5):713-724. doi: 10.1053/j.ajkd.2019.08.027. Epub 2019 Nov 12.
5
Pulmonary hypertension in CKD.慢性肾脏病相关肺动脉高压。
Am J Kidney Dis. 2013 Apr;61(4):612-22. doi: 10.1053/j.ajkd.2012.07.029. Epub 2012 Nov 17.
7
Therapeutic approaches for pulmonary hypertension in patients with chronic kidney disease.慢性肾脏病患者肺动脉高压的治疗方法。
Curr Opin Nephrol Hypertens. 2024 Sep 1;33(5):494-502. doi: 10.1097/MNH.0000000000001008. Epub 2024 Jun 19.

引用本文的文献

6
Kidney transplantation in the presence of pulmonary hypertension: A clinical dilemma.肺动脉高压情况下的肾移植:临床困境。
Heliyon. 2024 Oct 11;10(20):e39074. doi: 10.1016/j.heliyon.2024.e39074. eCollection 2024 Oct 30.

本文引用的文献

1
Pulmonary Hypertension Subtypes and Mortality in CKD.慢性肾脏病相关肺动脉高压的亚型与死亡率
Am J Kidney Dis. 2020 May;75(5):713-724. doi: 10.1053/j.ajkd.2019.08.027. Epub 2019 Nov 12.
2
Prostacyclin for pulmonary arterial hypertension.前列环素用于肺动脉高压
Cochrane Database Syst Rev. 2019 May 1;5(5):CD012785. doi: 10.1002/14651858.CD012785.pub2.
3
Phosphodiesterase 5 inhibitors for pulmonary hypertension.用于治疗肺动脉高压的磷酸二酯酶5抑制剂。
Cochrane Database Syst Rev. 2019 Jan 31;1(1):CD012621. doi: 10.1002/14651858.CD012621.pub2.
5
Pulmonary hypertension due to left heart disease.左心疾病所致肺动脉高压。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01897-2018. Print 2019 Jan.
6
Diagnosis of pulmonary hypertension.肺动脉高压的诊断。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01904-2018. Print 2019 Jan.
7
Risk stratification and medical therapy of pulmonary arterial hypertension.肺动脉高压的风险分层与药物治疗。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01889-2018. Print 2019 Jan.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验